Bone Turnover Markers in Primary Hyperparathyroidism

Journal of Clinical Densitometry

Volumn 16, Issue 1, 2013, Pages 22-27

  Costa, Aline G ^a,b   Bilezikian, John P ^a  

^a New York Presbyterian Columbia University Medical Center   (United States)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Bone turnover markers; Primary hyperparathyroidism; PTH

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; CINACALCET; CLODRONIC ACID; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DEOXYPYRIDINOLINE; ETIDRONIC ACID; HYDROXYLYSINE; HYDROXYLYSINE GLYCOSIDE; HYDROXYPROLINE; OSTEOCALCIN; PARATHYROID HORMONE; PYRIDINOLINE; RALOXIFENE; RISEDRONIC ACID; UNCLASSIFIED DRUG;

ARTICLE; BONE METABOLISM; BONE REMODELING; BONE TURNOVER; ESTROGEN THERAPY; HUMAN; HYPERCALCEMIA; OSSIFICATION; OSTEOLYSIS; PARATHYROIDECTOMY; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

BONE AND BONES; BONE REMODELING; CALCIMIMETIC AGENTS; DIPHOSPHONATES; ESTROGENS; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM, PRIMARY; PARATHYROIDECTOMY; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 84873143165     PISSN: 10946950     EISSN: 15590747     Source Type: Journal    
DOI: 10.1016/j.jocd.2012.11.004     Document Type: Article

References (54)

1. Mundy G.R., Cove D.H., Fisken R. Primary hyperparathyroidism: changes in the pattern of clinical presentation. Lancet 1980, 1(8182):1317-1320.
2. Parisien M., Cosman F., Mellish R.W., et al. Bone structure in post hyperparathyroid, osteoporotic, and normal women. J Bone Miner Res 1995, 10(9):1393-1399.
3. Bilezikian J.P., Brandi M.L., Rubin M., et al. Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features. J Intern Med 2005, 257(1):6-17.
4. Brixen K., Eriksen E.F. Validation of biochemical markers of bone turnover. Dynamics of Bone and Cartilage Metabolism 2006, 583-594. Academic Press, San Diego, CA. M.J. Seibel, S.P. Robins, J.P. Bilezikian (Eds.).
5. Seibel M.J. Molecular markers of bone metabolism in parathyroid disease. The Parathyroids: Basic and Clinical Concepts 2001, Vol. 1:399-409. Academic Press, San Diego, CA. 2nd ed.
6. Woitge H.W., Pecherstorfer M., Li Y., et al. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. J Bone Miner Res 1999, 14(5):792-801.
7. Alatalo S.L., Ivaska K.K., Waguespack S.G., et al. Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis). Clin Chem 2004, 50(5):883-890.
8. Guo C.Y., Thomas W.E., al-Dehaimi A.W., et al. Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 1996, 81(10):3487-3491.
9. Christiansen P., Steiniche T., Brixen K., et al. Primary hyperparathyroidism: biochemical markers and bone mineral density at multiple skeletal sites in Danish patients. Bone 1997, 21(1):93-99.
10. Valdemarsson S., Lindergard B., Tibblin S., et al. Increased biochemical markers of bone formation and resorption in primary hyperparathyroidism with special reference to patients with mild disease. J Intern Med 1998, 243(2):115-122.
11. Christiansen P., Steiniche T., Brixen K., et al. Primary hyperparathyroidism: short-term changes in bone remodeling and bone mineral density following parathyroidectomy. Bone 1999, 25(2):237-244.
12. Silverberg S.J., Gartenberg F., Jacobs T.P., et al. Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidism. J Clin Endocrinol Metab 1995, 80(3):723-728.
13. Bilezikian J.P., Khan A.A., Potts J.T. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 2009, 94(2):335-339.
14. Rubin M.R., Bilezikian J.P., McMahon D.J., et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 2008, 93(9):3462-3470.
15. Thorsen K., Kristoffersson A.O., Lorentzon R.P. Changes in bone mass and serum markers of bone metabolism after parathyroidectomy. Surgery 1997, 122(5):882-887.
16. Steiniche T., Christiansen P., Vesterby A., et al. Primary hyperparathyroidism: bone structure, balance, and remodeling before and 3 years after surgical treatment. Bone 2000, 26(5):535-543.
17. Garton M., Martin J., Stewart A., et al. Changes in bone mass and metabolism after surgery for primary hyperparathyroidism. Clin Endocrinol (Oxf) 1995, 42(5):493-500.
18. Alonso S., Ferrero E., Donat M., et al. The usefulness of high preoperative levels of serum type I collagen bone markers for the prediction of changes in bone mineral density after parathyroidectomy. J Endocrinol Invest 2012, 35:640-644.
19. Tamura Y., Araki A., Chiba Y., et al. Remarkable increase in lumbar spine bone mineral density and amelioration in biochemical markers of bone turnover after parathyroidectomy in elderly patients with primary hyperparathyroidism: a 5-year follow-up study. J Bone Miner Metab 2007, 25(4):226-231.
20. Boudou P., Ibrahim F., Cormier C., et al. Potential utility of high preoperative levels of serum type I collagen markers in postmenopausal women with primary hyperparathyroidism with respect to their short-term variations after parathyroidectomy. J Bone Miner Metab 2009, 27(2):240-246.
21. Guo C.Y., Holland P.A., Jackson B.F., et al. Immediate changes in biochemical markers of bone turnover and circulating interleukin-6 after parathyroidectomy for primary hyperparathyroidism. Eur J Endocrinol 2000, 142(5):451-459.
22. Grey A., Mitnick M.A., Shapses S., et al. Circulating levels of interleukin-6 and tumor necrosis factor-alpha are elevated in primary hyperparathyroidism and correlate with markers of bone resorption-a clinical research center study. J Clin Endocrinol Metab 1996, 81(10):3450-3454.
23. Stilgren L.S., Hegedus L.M., Beck-Nielsen H., et al. Osteoprotegerin levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. Calcif Tissue Int 2003, 73(3):210-216.
24. Krause C., Korchynskyi O., de Rooij K., et al. Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways. J Biol Chem 2010, 285(53):41614-41626.
25. Li X., Zhang Y., Kang H., et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 2005, 280(20):19883-19887.
26. Semenov M., Tamai K., He X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem 2005, 280(29):26770-26775.
27. van Bezooijen R.L., Svensson J.P., Eefting D., et al. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res 2007, 22(1):19-28.
28. Costa A.G., Cremers S., Rubin M.R., et al. Circulating sclerostin in disorders of parathyroid gland function. J Clin Endocrinol Metab 2011, 96(12):3804-3810.
29. van Lierop A.H., Witteveen J.E., Hamdy N.A., et al. Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls. Eur J Endocrinol 2010, 163(5):833-837.
30. Ardawi M.S., Al-Sibiany A.M., Bakhsh T.M., et al. Decreased serum sclerostin levels in patients with primary hyperparathyroidism: a cross-sectional and a longitudinal study. Osteoporos Int 2012, 23(6):1789-1797.
31. Gallagher J.C., Nordin B.E. Treatment with oestrogens of primary hyperparathyroidism in post-menopausal women. Lancet 1972, 1(7749):503-507.
32. Marcus R., Madvig P., Crim M., et al. Conjugated estrogens in the treatment of postmenopausal women with hyperparathyroidism. Ann Intern Med 1984, 100(5):633-640.
33. Selby P.L., Peacock M. Ethinyl estradiol and norethindrone in the treatment of primary hyperparathyroidism in postmenopausal women. N Engl J Med 1986, 314(23):1481-1485.
34. Grey A.B., Stapleton J.P., Evans M.C., et al. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial. Ann Intern Med 1996, 125(5):360-368.
35. Orr-Walker B.J., Evans M.C., Clearwater J.M., et al. Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four-year follow-up and comparison with healthy postmenopausal women. Arch Intern Med 2000, 160(14):2161-2166.
36. Diamond T., Ng A.T., Levy S., et al. Estrogen replacement may be an alternative to parathyroid surgery for the treatment of osteoporosis in elderly postmenopausal women presenting with primary hyperparathyroidism: a preliminary report. Osteoporos Int 1996, 6(4):329-333.
37. Mosekilde L. Primary hyperparathyroidism and the skeleton. Clin Endocrinol (Oxf) 2008, 69(1):1-19.
38. Zanchetta J.R., Bogado C.E. Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism. J Bone Miner Res 2001, 16(1):189-190.
39. Rubin M.R., Lee K.H., McMahon D.J., et al. Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2003, 88(3):1174-1178.
40. Shoback D.M., Bilezikian J.P., Turner S.A., et al. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 2003, 88(12):5644-5649.
41. Peacock M., Bilezikian J.P., Klassen P.S., et al. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2005, 90(1):135-141.
42. Iglesias P., Ais G., Gonzalez A., et al. Acute and one-year effects of cinacalcet in patients with persistent primary hyperparathyroidism after unsuccessful parathyroidectomy. Am J Med Sci 2008, 335(2):111-114.
43. Sajid-Crockett S., Singer F.R., Hershman J.M. Cinacalcet for the treatment of primary hyperparathyroidism. Metabolism 2008, 57(4):517-521.
44. Marcocci C., Chanson P., Shoback D., et al. Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. J Clin Endocrinol Metab 2009, 94(8):2766-2772.
45. Peacock M., Bilezikian J.P., Bolognese M.A., et al. Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity. J Clin Endocrinol Metab 2011, 96(1):E9-E18.
46. Faggiano A., Di Somma C., Ramundo V., et al. Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism. Endocrine 2011, 39(3):283-287.
47. Kaplan R.A., Geho W.B., Poindexter C., et al. Metabolic effects of diphosphonate in primary hyperparathyroidism. J Clin Pharmacol 1977, 17(7):410-419.
48. Shane E., Baquiran D.C., Bilezikian J.P. Effects of dichloromethylene diphosphonate on serum and urinary calcium in primary hyperparathyroidism. Ann Intern Med 1981, 95(1):23-27.
49. Rossini M., Gatti D., Isaia G., et al. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Miner Res 2001, 16(1):113-119.
50. Chow C.C., Chan W.B., Li J.K., et al. Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2003, 88(2):581-587.
51. Khan A.A., Bilezikian J.P., Kung A.W., et al. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004, 89(7):3319-3325.
52. Khan A.A., Bilezikian J.P., Kung A., et al. Alendronate therapy in men with primary hyperparathyroidism. Endocr Pract 2009, 15(7):705-713.
53. Parker C.R., Blackwell P.J., Fairbairn K.J., et al. Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study. J Clin Endocrinol Metab 2002, 87(10):4482-4489.
54. Reasner C.A., Stone M.D., Hosking D.J., et al. Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate. J Clin Endocrinol Metab 1993, 77(4):1067-1071.